Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

  title={Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis},
  author={Derick T. Wade and Petra Makela and Heather House and Cynthia Bateman and Philip J. Robson},
  journal={Multiple Sclerosis},
  pages={639 - 645}
The object of this study was to monitor the safety and efficacy of long-term use of an oromucosal cannabis-based medicine (CBM) in patients with multiple sclerosis (MS). A total of 137 MS patients with symptoms not controlled satisfactorily using standard drugs entered this open-label trial following a 10-week, placebo-controlled study. Patients were assessed every eight weeks using visual analogue scales and diary scores of main symptoms, and were followed for an average of 434 days (range: 21… 

Figures and Tables from this paper

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

  • Paul F. Smith
  • Psychology
    Therapeutics and clinical risk management
  • 2010
The available clinical trial data suggest that the adverse side effects associated with using CBMEs are generally mild, but there may be reason to be concerned about the use of therapeutic cannabinoids by adolescents, people predisposed to psychosis and pregnant women.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

Clinical studies on cannabis-based medicine extract (CBME), in particular nabiximols, in spasticity, as well as pain, and bladder dysfunction in MS are analyzed.

Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

Current evidence for the efficacy and safety of δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity is reviewed.

Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?

Use of cannabis in patients with multiple sclerosis from Argentina.

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine

  • W. Notcutt
  • Medicine, Psychology
    Primary Health Care Research & Development
  • 2012
The majority of respondents and their caregivers reported improvements across a range of daily functional activities, alongside a reduction in the use of concomitant anti-spasticity medication and in theUse of other healthcare resources.

Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naïve patients with MS, but the positive correlation between blood levels of &Dgr;-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings, interpersonal sensitivity, aggressiveness, and paranoiac features might arise.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

The pharmacological properties, clinical efficacy and tolerability of THC/CBD in MS patients is studied and adverse effects are usually mild or moderate and the low rate of drug discontinuation provides good evidence of long-term tolerability.

Cannabis and Multiple Sclerosis.

Nabiximols is safe and effective for patients with multiple sclerosis whose spasticity could not be treated with the first-line oral drugs, and there is no scientific evidence that smoking marijuana can be beneficial to patients with MS.



An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Urinary urgency, the number and volume of incontinence episodes, frequency and nocturia all decreased significantly following treatment with cannabis-based medicinal extracts, suggesting that cannabis- based medicinal extracts are a safe and effective treatment for urinary and other problems in patients with advanced MS.

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P- 0.001), there were no significant adverse effects on cognition or mood and intoxication was generally mild.

The perceived effects of smoked cannabis on patients with multiple sclerosis.

The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated.

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.

There was significant improvement in patient ratings of spasticity compared to placebo at doses greater than 7.5 mg, suggesting a role for THC in the treatment ofSpasticity in multiple sclerosis.

Cognitive functioning of long-term heavy cannabis users seeking treatment.

It is confirmed that long-term heavy cannabis users show impairments in memory and attention that endure beyond the period of intoxication and worsen with increasing years of regular cannabis use.

Psychiatric effects of cannabis

  • A. Johns
  • Medicine, Psychology
    British Journal of Psychiatry
  • 2001
To re-evaluate the adverse effects of cannabis in the general population and among vulnerable individuals, including those with serious psychiatric disorders, a wide-ranging review of the topics related to these issues is conducted.